Senner Christopher J. 4

What Happened
Christopher J. Senner, a director of Quince Therapeutics, was granted a derivative award covering 21,810 shares on 2026-01-02. The Form 4 reports an acquisition at $0.00 per share (reported value $0) — the award is a stock‑option grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-02; Form 4 filed: 2026-01-21 (appears later than the 2-business‑day Form 4 rule).
• Instrument: Derivative (stock option award) for 21,810 shares; reported price per share $0.00; reported dollar amount $0.
• Shares owned after the transaction: not specified in the filing.
• Footnote: The award vests in equal quarterly installments over one year. Senner elected to receive the stock options in lieu of his 2026 outside director cash retainer under the company’s policy.

Context
This is an award of options granted as director compensation, not a market buy or sale. Vesting over one year means the options become exercisable in quarterly tranches; the filing does not show an immediate exercise or sale. Such grants are routine for non-employee directors and reflect compensation choices rather than an open‑market bullish or bearish trade.